Technology
Health
Biotechnology

Leap Therapeutics

$2.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-5.40%) Today
+$0.00 (0.25%) After Hours

Why Robinhood?

You can buy or sell LPTX and other stocks, options, ETFs, and crypto commission-free!

About

Leap Therapeutics, Inc. Common Stock, also called Leap Therapeutics, is a clinical stage biopharmaceutical company. Read More It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics. The firm's pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Employees
22
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
31.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
288.07K
High Today
$2.25
Low Today
$1.89
Open Price
$2.16
Volume
837.27K
52 Week High
$10.25
52 Week Low
$1.35

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2017 IPO

News

Yahoo FinanceMar 11

Four Tech Stocks Setting The Pace On Monday

CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The success of the tech stock market is directly correlated to the operating assumption that tech companies are prepared to meet the rising challenges presently facing society.

2,382
PR NewswireMar 8

Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

CAMBRIDGE, Mass., March 8, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer, being held March 16-19, 2019 in Honolulu, HI. About the DKN-01 P204 clinical trial The P204 study is a Phase 2 basket study of DKN-01 as both a monotherapy and in combination with paclitaxel in patients with ...

798

Earnings

-$0.85
-$0.71
-$0.58
-$0.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.57 per share
Actual
Expected Today, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.